PDS Biotechnology Corp
Financial highlights
| Metric | FY 12/31/25 | FY 09/30/25 | FY 06/30/25 | FY 03/31/25 | FY 12/31/24 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $19.0M | — | — | — | $22.6M |
| Operating expenses | $31.5M | — | — | — | $36.3M |
| Operating income | -$31.5M | — | — | — | -$36.3M |
| Interest expense | $5.3M | — | — | — | $4.7M |
| Pretax income | -$35.7M | — | — | — | -$38.5M |
| Income tax expense | -$1.2M | — | — | — | -$869,169 |
| Net income | -$34.5M | — | — | — | -$37.6M |
| Balance Sheet | |||||
| Cash and equivalents | $26.7M | — | — | — | $41.7M |
| Current assets | $28.3M | — | — | — | $45.1M |
| Total assets | $30.5M | — | — | — | $45.4M |
| Current liabilities | $9.5M | — | — | — | $17.1M |
| Total liabilities | $21.2M | — | — | — | $26.4M |
| Stockholders' equity | $9.3M | $9.5M | $16.0M | $22.4M | $19.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$27.8M | — | — | — | -$35.0M |
| Depreciation and amortization | $21,836 | — | — | — | $21,112 |
| Stock-based compensation | $4.1M | — | — | — | $6.8M |
| Capital expenditure | $0 | — | — | — | $29,000 |
| Free cash flow | -$27.8M | — | — | — | -$35.1M |
Shares outstanding 55.8M · Free float 85.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.